Summary & Overview
CPT 96912: Photochemotherapy (PUVA) with Psoralen and UVA
CPT code 96912 represents photochemotherapy (PUVA) using psoralens plus ultraviolet A light to manage chronic dermatologic conditions such as psoriasis and vitiligo. Nationally, PUVA remains a clinically important option for patients who have not responded to first-line topical or phototherapy approaches; accurate coding for 96912 matters for clinical documentation, appropriate utilization tracking, and payer adjudication.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for PUVA therapy, common sites of service where the procedure is delivered, and benchmarking and coverage themes that influence payment and utilization. The publication outlines typical billing considerations for outpatient dermatology settings and highlights policy updates and payer practices that affect prior authorization, medical necessity determinations, and bundling rules.
This summary equips clinicians, billers, and policy analysts with essential information about CPT code 96912, clarifies the clinical role of PUVA therapy, and frames the reimbursement and coverage environment at a national level. Data not available in the input will be noted where applicable in supporting sections.
Billing Code Overview
CPT code 96912 describes a photochemotherapy service using psoralens combined with ultraviolet A (PUVA) radiation to treat dermatologic conditions such as psoriasis and vitiligo. This procedure involves administering a photosensitizing agent (psoralen) followed by controlled exposure to UVA light to modulate skin cell behavior and pigmentation.
Service Type: Photochemotherapy / PUVA therapy
Typical Site of Service: Outpatient dermatology clinic or ambulatory treatment center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 35–60 year-old adult with moderate to severe plaque psoriasis or widespread vitiligo referred to dermatology after topical therapies and/or systemic agents provided inadequate control. The clinical workflow begins with a consultation visit including history, skin examination, and documentation of diagnosis and affected body surface area. Baseline photos and measurement of percent body surface area or a psoriasis severity score (e.g., PASI) are often recorded. The provider selects psoralen plus ultraviolet A (PUVA) therapy using oral or topical psoralen depending on extent and skin location. On treatment days the patient receives pre-treatment instructions, ingestes prescribed psoralen (or applies topical psoralen), and is escorted to the phototherapy suite. The technician or nurse verifies patient identity, documents the time and dose of psoralen, assesses eye protection and contraindications, and delivers controlled UVA exposure with calibrated equipment. Sessions are typically administered two to three times weekly over multiple weeks with dose adjustments based on skin response and side effects. Photoprotection counseling, monitoring for erythema, and periodic dermatology follow-up for efficacy and long-term risks (including photodamage and skin cancer surveillance) are part of the ongoing clinical workflow. Typical site of service is an outpatient dermatology clinic, ambulatory surgical center, or hospital outpatient department equipped with phototherapy units.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Service was performed by the billing physician or qualified healthcare professional |